ZFIN ID: ZDB-FISH-150901-26869
Fish name: wprt8Tg
Genotype: wprt8Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by wprt8Tg
No data available
GENE EXPRESSION
Gene expression in wprt8Tg
Protein expression No data available
Reporter gene expression
Expressed Gene Structure Conditions Figures
Venus control Fig. S5 from McMenamin et al., 2014
chemical treatment: pharmaceutical Fig. S5 from McMenamin et al., 2014
PHENOTYPE
Phenotype in wprt8Tg
Phenotype Conditions Figures
barbel absent, abnormal chemical treatment: pharmaceutical Fig. S5 from McMenamin et al., 2014
blood glucose increased amount, abnormal chemical treatment by injection: metronidazole, chemical treatment by injection: glucose, chemical ablation: thyroid follicle Fig. 7 from Matsuda et al., 2017
blood glucose increased amount, abnormal chemical treatment by injection: metronidazole, chemical ablation: thyroid follicle Fig. 7 from Matsuda et al., 2017
cranium deformed, abnormal chemical treatment: pharmaceutical Fig. S5 from McMenamin et al., 2014
melanocyte increased amount, abnormal chemical treatment: pharmaceutical Fig. 1Fig. 4 from McMenamin et al., 2014
melanocyte cell death decreased process quality, abnormal chemical treatment: pharmaceutical Fig. 4 from McMenamin et al., 2014
melanocyte cell division increased process quality, abnormal chemical treatment: pharmaceutical Fig. 4 from McMenamin et al., 2014
pancreas ins expression decreased amount, abnormal chemical treatment by injection: metronidazole, chemical ablation: thyroid follicle Fig. 7 from Matsuda et al., 2017
pancreas gcgb expression increased amount, abnormal chemical treatment by injection: metronidazole, chemical ablation: thyroid follicle Fig. 7 from Matsuda et al., 2017
pancreas gcga expression increased amount, abnormal chemical treatment by injection: metronidazole, chemical ablation: thyroid follicle Fig. 7 from Matsuda et al., 2017
scale condensed, abnormal chemical treatment: pharmaceutical Fig. S5 from McMenamin et al., 2014
swim bladder development delayed, abnormal chemical treatment: pharmaceutical Fig. S5 from McMenamin et al., 2014
thyroid follicle absent, abnormal chemical treatment: pharmaceutical Fig. S5 from McMenamin et al., 2014
whole organism neurod1 expression decreased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism mnx1 expression decreased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism ins expression decreased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism pax6b expression decreased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism pax4 expression decreased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism arxa expression increased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism gcga expression increased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
whole organism glucose increased amount, abnormal chemical ablation: thyroid follicle, chemical treatment by environment: metronidazole Fig. 6 from Matsuda et al., 2017
xanthophore absent, abnormal chemical treatment: pharmaceutical Fig. 1 from McMenamin et al., 2014
xanthophore decreased amount, abnormal chemical treatment: pharmaceutical Fig. 1Fig. S5 from McMenamin et al., 2014

CITATIONS  (4)